A novel loop-mediated isothermal amplification method for efficient and robust detection of EGFR mutations

SHO HORIUCHI1,2, YUICHI SAITO2,3, ATSUKA MATSUI4, NOBUMASA TAKAHASHI3, TOMOHIKO IKEYA3, EISHIN HOSHI3, YOSHIHIKO SHIMIZU5 and MASANORI YASUDA1

1Department of Pathology, Saitama Medical University International Medical Center, Hidaka 350-1298; 2Department of Thoracic Surgery, Saitama Cardiovascular and Respiratory Center, Kumagaya, Saitama 360-0197; 3Department of Surgery, Teikyo University School of Medicine, Tokyo 173-8605; 4Fundamental Research Laboratory, Fundamental Technology Research Department, Eiken Chemical Co., Ltd., Otawara, Tochigi 324-0036; 5Department of Pathology, Saitama Cardiovascular and Respiratory Center, Kumagaya, Saitama 360-0197, Japan

Received July 18, 2019; Accepted December 12, 2019

DOI: 10.3892/ijo.2020.4961

Abstract. The activation of somatic mutations conferring sensitivity to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors has been widely used in the development of advanced or metastatic primary lung cancer therapy. Therefore, identification of EGFR mutations is essential. In the present study, a loop-mediated isothermal amplification (LAMP) method was used to identify EGFR mutations, and its efficiency was compared with the Therascreen quantitative PCR assay. Using LAMP and Therascreen to analyze surgically resected tissue samples from patients with pulmonary adenocarcinoma, EGFR mutations were observed in 32/59 tumor samples (LAMP) and 33/59 tumor samples (Therascreen). Notably, the LAMP assay identified one tumor as wild-type, which had previously been identified as a deletion mutation in exon 19 via the Therascreen assay (Case X). However, the direct sequencing to confirm the EGFR status of the Case X adhered to the results of the LAMP assay. Further experiments using Case X DNA identified this exon 19 deletion mutation using both methods. In addition, a novel deletion mutation in exon 19 of the EGFR was identified. Overall, the present study shows that the LAMP method may serve as a valuable alternative for the identification oncogene mutations.

Introduction

Lung cancer has the highest morbidity and mortality of all malignancies in the USA in 2011 and 2013 (1,2). Non-small cell lung carcinoma (NSCLC) is the most common form of lung cancer, accounting for 70−85% of cases and is primarily treated using systemic chemotherapy (3). However, NSCLC treatment has evolved due to the development of therapy targeting the activation of mutations in the epidermal growth factor receptor (EGFR) (4).

EGFR activation is caused by genetic mutations, conferring susceptibility to EGFR tyrosine kinase inhibitor (TKI) treatment, and was first reported in 2004 (5). EGFR mutations of pulmonary adenocarcinoma are present in 5-15% of the Caucasian population and 40-55% of the East Asian population (6-8). Clinical trials have shown that patients with pulmonary adenocarcinoma with an EGFR mutation exhibit clinical responses to orally administered EGFR inhibitors (5,7,9). In 2016, Lin et al (4) reported that 20/137 (14.6%) patients with EGFR-mutant metastatic lung adenocarcinoma had a survival time of 5-years (4). Therefore, detection of EGFR mutations is an important step in the treatment-decision pathway for patients with pulmonary adenocarcinoma.

Previously, direct DNA sequencing was the standard method for detecting genetic mutations (10); however, at present, several alternative methods for mutation testing have been developed (11,12). For example, the Therascreen EGFR PCR kit® (Qiagen, Inc.) is a commercial quantitative (q)PCR kit and has been widely adopted for clinical practice; however, this method is time-consuming and possesses certain procedural complexities, for example, requiring several temperature changes during DNA amplification (11). Next-generation sequencing has improved the efficiency of oncogene testing by high-throughput sequencing, which can detect dozens of mutations at the same time, but the high-cost of this technique limits its clinical usage (13,14). Therefore, detecting oncogenic mutations using a simple, easy and highly reproducible method remains a challenge.

Loop-mediated isothermal amplification (LAMP) is a new PCR based method with high levels of specificity and
amplification efficiency and utilizes six primers (15). This method is performed under isothermal conditions, thereby enabling rapid amplification. Due to the high specificity and rapid detection quality of LAMP, this method has been widely used in the fields of bacteriology (16) and virology (17,18). However, to the best of our knowledge, there are very few studies reporting the value of LAMP in determining EGFR mutations. Therefore, the present study aimed to detect EGFR mutations in surgically resected tumor tissues from patients with pulmonary adenocarcinoma using this method, as detection of EGFR mutations is one a key examination for patients with pulmonary adenocarcinoma (4,5,7,9). In addition, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of LAMP was evaluated and compared with the Therascreen EGFR PCR kit®.

Materials and methods

**Tumor tissue samples.** The tumor tissues were surgically resected from 189 consecutive patients diagnosed with pulmonary adenocarcinoma by the expert pathologist at The Saitama Cardiovascular and Respiratory Center (Kumagaya, Japan) between January 2016 and October 2017. All pathological diagnosis was determined on the basis of the WHO classification version 8 (19) by an expert pathologist, who normally makes a diagnosis using HE-stained slides using light microscope (Nikon Co., ECLIPSE Ni-u) from a low magnification to a high magnification. The inclusion criteria were as follows: i) Surgically resected tissue of primary lung cancer; ii) pulmonary adenocarcinoma; iii) enough volume materials for molecular testing; and iv) informed written consent from patients. Conversely, cases with no informed consent or less volume sample were excluded. Clinical characteristics of the 59 patients are presented in Table I. The mean patient age was 69.6 years and included 28 males and 31 females. All samples were fixed with 10% buffer formalin at room temperature (24-36 h) to create formalin-fixed, paraffin-embedded (FFPE) tumor blocks at Department of Pathology in Saitama Cardiovascular and Respiratory Center. Hematoxylin-eosin staining was performed by the standard method using Tissue-Tek Prisma (Sakura Finetek Japan Co., Ltd.) according to the manufacturer's protocol. Prior to DNA extraction, the tumor content of each sample was assessed using light microscopy at x10 and x100 magnification, to ensure efficient PCR amplification. After sections were deparaffinized with xylene and hydrated through a graded series of ethanol (100, 100, 85 and 70% ethanol), DNA from the tissue blocks was extracted using the QIAampTM DNA FFPE Tissue kit® (Qiagen, Inc.) and analyzed using a QIAcube Robot® (Qiagen, Inc.) according to the manufacturer's protocols (20).

**Therascreen qPCR mutation analysis.** The presence of EGFR mutations was determined using a Therascreen EGFR PCR kit® (Qiagen, Inc.) according to the manufacturer's protocols (21).

**LAMP mutation analysis**

**Primer design.** A primer set for LAMP amplification of the partial sequence of the EGFR gene (NG_007726) was designed using Primer Explorer (primerexplorer.jp/e/). Fig. 1 presents the sequences of the primers used with forward and backward outer primers (F3 and B3), forward and backward inner primers (FIP and BIP) and forward and back-loop primers (LF and LB). The primers were synthesized and purified by Eurofin Genomics. Block oligo and fluorophore-labelled probes were synthesized and purified by Japan Bio Services Co., Ltd., or Gene Design, Inc.

**LAMP assay.** LAMP assays were performed using the 25 reaction volume with 30 mM KCl, 1.8% Dextran, 14 mM Tricine-NaOH (pH 8.8), 0.1% n-heptyl, 0.5% Tween-20, 0.3% Fish collagen peptide, 1 mM DTT, 1.7 mM each dNTPs, 8.2 mM MgSO4, 1.6 µM each of the forward and backward inner primer, 0.8 µM each of the forward and backward loop primer, 0.2 µM forward and backward outer primer, 1.2 µM block oligo, 0.04 µM fluorophore-labeled probe, 0.0375 x Gel green and 12.3 units Bst DNA polymerase. KCl, Dextran, Tricine NaOH, n-heptyl, Tween-20, Fish collagen peptide, DTT, and MgSO4 were obtained from FUJIFILM Wako Pure Chemical Corporation (http://ffwk.fujifilm.co.jp/en/index.html). dNTPs were obtained from NIPPON GENE CO., Ltd. (https://www.nippongene.com/english/index.html). Gel green was obtained from Biotium (https://biotium.com/). Bst DNA polymerase was obtained from New England Biolabs Inc. (https://international. neb.com). The LAMP reaction was run for 120 min at 65°C using a LightCycler 480® (Roche Diagnostics K.K.).

**Detection of the LAMP products.** Melting curve analysis was used to detect LAMP products. The LAMP amplicons were denatured at 95°C for 5 min, followed by hybridization at 37°C for 5 min. Subsequently, the temperature was gradually raised to 80°C and the fluorescent intensity was measured 7 times per 1°C increment. The obtained data were analyzed by the LightCycler 480® software (version 1.5.1.62; https://lifescience.roche.com/global/en/products/lightcycler14301-480-software-version-15.html) to calculate melting peak.

**Sensitivity of LAMP and Therascreen assays.** In order to evaluate the analytical sensitivity, an artificial gene harboring an EGFR L858R mutation (c.2573T>G) as a plasmid DNA was obtained from Eurofin Genomics. The plasmid DNA that had been linearized using EcoR V and Xho I were extracted from 1% agarose gel after 40 min electrophoresis with 100 V. The agarose gel was stained by 0.5 µg ethidium bromide (Tokyo Chemical Industry Co., Ltd.; https://www.tcichemicals.com/en/shop/en/p/commodity/E0370/) for 30 min and observed by LuminoGraph 2 (ATTO Corporation; https://www.atto.co.jp/eng). Then, this DNA fragment was added to human pooled genomic DNA (Promega Corporation) to prepare several spiked-in samples with different concentrations for a validation of lower limit of detection. In the present study, 1500.0, 150.0, 75.0, 15.0, 7.5, 3.0, and 1.5 copies of DNA fragment harboring EGFR L858R mutation were added to 1500 copies of genomic DNA, resulting in mutation rates of 50.00, 9.09, 4.76, 0.99, 0.50, 0.20, 0.10 and 0.00%, respectively. Genetic analysis of each of these samples was conducted three times using PCR and LAMP.

**Direct sequence method.** Direct sequencing of EGFR exon 19, S768I and G719X regions were conducted by using BigDye® Direct Cycle Sequencing Kit (Thermo Fisher Scientific,
Inc.) and a ABI PRISM 310 Genetic Analyzer® (Applied Biosystems; Thermo Fisher Scientific, Inc.) to confirm the EGFR mutation status in Case-X. The data were analyzed using Genetyx (version 13.0; https://www.genetyx.co.jp/) and FinchTV (version 1.4.0; https://digitalworldbiology.com/FinchTV). The primers had the following sequences: Exon 19, forward TCCCAGAAGGTGAGAAAGT, reverse: AGA GCT AGA AAG GGA AAG ACA; S768I:, forward: CCT CCA GGA AGC CTA CGT, reverse: GTC TTT GTG TTC CCG GAC AT; and G719X, forward: CCC TTG TCT CTG TGT TCT TG, reverse: TAC ACC GTG CCG AAC GC.

Statistical analysis. All statistical analysis performed using SPSS version 24 for Windows® (IBM Corp). The clinical sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of conventional PCR testing of the LAMP method were calculated through comparison with the Therascreen PCR, which was considered as the current gold standard test for detecting EGFR mutations in the present study.

Results

Characteristics of patients with pulmonary adenocarcinoma. Mean age of the 59 patients was 69.6 years and included 28 males and 31 females. Of these, 27 were non-smokers (45.8%). The number in pathological stage IA1, IA2, IA3, IB, IIA, IIB, IIIA was 14 (23.7%), 20 (33.9%), 6 (10.2%), 4 (6.8%), 1 (1.7%), 3 (5.1%), and 11 (18.6%), respectively. All patients had been diagnosed with pulmonary adenocarcinoma, including of 34 papillary predominant (57.6%), 7 solid predominant (11.9%), 3 acinar predominant (5.1%), 7 invasive mucinous (11.9%), 4 lepidic predominant (6.8%) and 4 minimally invasive adenocarcinoma cases (6.8%; all Table I).

Therascreen EGFR PCR mutation analysis. Among 59 pulmonary tumors, there were 26 tumors with EGFR wild type and 33 tumors with EGFR mutations (Table II). Overall, 18 exon 21 L858R point mutations (54.5%), 12 exon 19 deletions (36.4%), 2 simultaneous exon 18 G719X point mutation/exon 20 S768I point mutation (6.1%) and 1 exon 20 SS761I point mutation (3.0%) were detected in the pulmonary tumors with EGFR mutations (Table II).

LAMP EGFR mutation analysis. The LAMP assay detected 27 EGFR wild types and 32 EGFR mutations (Table II). Among 32 EGFR mutations, 18 exon 21 L858R point mutations (54.5%), 11 exon 19 deletions (33.3%), 2 simultaneous exon 18 G719X point mutation/exon 20 S768I point mutations (6.1%) and 1 exon 20 SS761I point mutation alone (3.0%) were identified (Table II).

Comparison of results of Therascreen PCR and LAMP assays. Table II demonstrates that 33 EGFR mutations in the LAMP assay (18 samples with exon 21 L858R, 11 samples with exon 19 deletions, 1 sample with exon 20 S768I, and 2 samples with exon 18 G719X and exon 20 S768I), and that 32 EGFR mutations in the Therascreen assay (18 samples with exon 21 L858R, 12 samples with exon 19 deletions, 1 sample with exon 20 S768I, and 2 samples with exon 18 G719X and exon 20 S768I); i.e., there was one case showing EGFR wild type of the LAMP but one deletion mutation in exon 19 of the Therascreen PCR (Table III). As assuming that the results of Therascreen PCR assay was true, qualitative analysis was performed for calculating sensitivity, specificity, PPV, NPV and accuracy of the LAMP assay. These values were 97.0%, 100.0, 100.0, 96.3 and 98.3%, respectively. Furthermore, a genetic analysis was performed to evaluate the detection rate of EGFR mutations in different concentrations. The minimum...
concentration for EGFR mutation detection was 4.8% of DNA sample in Therascreen assay (Table SI). On the other hand, 0.1% was the minimum concentration in LAMP assay, since LAMP assay demonstrated one success of the detection per 3 tests at the level of 0.1, 0.5 and 1.0% concentrations and all positive per 3 tests at >4.8% concentration (Table SI).

**Direct sequencing of Case X.** It was observed that a single case deviated in the identification of the mutation in exon 19 between Therascreen PCR and the LAMP assay. To confirm this result, direct sequencing of the target site of exon 19 was performed. Direct sequencing results demonstrated no mutation in exon 19 in Case X, which was concordant with the results of the LAMP assay.

To reconfirm the status of EGFR mutation in Case X, four additional FFPE tissue blocks in Case X were used to extract further DNA samples. The hematoxylin-eosin (HE) images of these FFPE blocks are presented in Fig. 2. Following removal of normal lung tissues, DNA samples were extracted as aforementioned, and investigated using Therascreen EGFR PCR and a LAMP assay. In all the four samples, the deletion mutation in exon 19 was identified using both Therascreen PCR and LAMP assays. Furthermore, direct sequencing revealed a novel exon 19 EGFR deletion mutation in samples a and b; NG_007726.3: g.160744_160761delinsGCA represented the deletion of nucleotides g.160744 to g.160761 (ATTAAGAGAAGCAACATC, data not shown), which were replaced by a GCA nucleotide triplet, changing GGAATTAAGAGAAGCAACATCTCC to GGAGCATCC (data not shown), resulting in shortening substitution in the protein (p.Leu747_Ser752delinsHis).

**Discussion**

EGFR mutations in pulmonary adenocarcinoma are associated with sensitivity to TKI therapy. Hence the identification of EGFR mutations has become a standard analysis in the treatment pathway of patients with pulmonary adenocarcinoma. Although there are a number of methods available, there is no standardized approach to satisfy the practical clinical requirements of simplicity, rapid and cheap. Several PCR based methods have previously been used as a routine test for the detection of EGFR status in United States, European Union, Japan and China, including the Scorpion Amplification Refractory Mutation System (ARMS)® (22), such as Therascreen PCR assay. This method was approved by the FDA as a standard approach for EGFR gene analysis in lung cancer (fda.gov/medical-devices/recently-approved-devices/therascreenR-fg fr-rgq-pcr-kit-p180043); however, although stable and reliable, this approach has procedural complexities, including complex settings and controls for the temperature at several times using a
thermal cycler. Alternatives, such as PCR-Invader® (23), peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp (24) and Cycleave PCR™ (25), have been developed in Japan and are commercially used in centralized laboratories. The sensitivity of the PNA-LNA PCR clamp is >97% with 100% specificity (26) and the accuracy of Cycleave PCR is 96.7% (27), so it was the same for our results as it was those.

LAMP is a new PCR method and is considered to be a robust approach for gene analysis as it does not require sophisticated or expensive equipment, such as a thermal cycler necessary for PCR (15). Therefore, the LAMP method may have potential to decrease the costs of gene analysis. Previous studies have demonstrated the value of LAMP in field of bacteriology and virology (15,17,28,29); however, few studies have reported the value of LAMP in oncology. Ikeda et al (30) used LAMP assays to detect EGFR mutations in NSCLC, demonstrating the value of LAMP, but only the L858R mutation was studied. Therefore, the present study aimed to investigate other EGFR mutations, including those in exon 19, exon 21 and other minor mutations using LAMP assays.

The sensitivity, specificity, PPV, NPV and accuracy values of LAMP for EGFR mutations compared with the Therascreen assay method were 97, 100, 100, 96.3 and 98.3%, respectively, demonstrating the potential of LAMP as an efficient alternative approach to oncogene mutation analyses. To evaluate the sensitivity of these two assays, a genetic analysis was performed to investigate the minimum concentration of EGFR mutation detection in both methods. The minimum concentration for LAMP was 4.8% and there were no detection under 1.0% in the Therascreen assay. Therefore, the minimum concentration for the LAMP assay is ~50 times higher than 4.8% in the Therascreen assay. With almost equal efficiency, detection of the exon 19 mutation in Case X using the Therascreen method suggested that LAMP, as well as direct sequence methods, could identify false negatives. However, additional experiments investigating Case X tumor tissues demonstrated the presence of deletion mutations in exon 19. The direct sequence method has reported low sensitivity (31,32), whereas the Therascreen method was generally recognized as a promising method (11,12). However, the identified mutation should be simplified, and an improved, faster and cheaper method of identification should be developed for its clinical application.

The additional Case X experiments also identified a novel EGFR mutation using direct sequencing which was not identified using Therascreen or LAMP; however, this mutation may have been detected as an exon 19 deletion by the primers of the similarly targeted mutation. However, the details of the primer of LAMP method could not be disclosed due to the policies of Eiken Co., Ltd., and further information concerning the primers of Therascreen EGFR PCR kit could not be obtained due to the patent. Furthermore, the present study noted that this novel mutation was not included in the COSMIC database and that no previous studies had reported this mutation. Therefore, the present study is the first report this EGFR mutation, to the best of our knowledge.

In conclusion, the LAMP method may be a valuable alternative for the identification of oncogenic mutations in lung cancer. Currently, the study group is developing a new method of detecting oncogenes using liquid biopsies (data not shown). In addition, a novel mutation, NG_007726.3:g.160744_160761delinsGCA, was identified exon 19 of EGFR. However, this needs further validation before clinical use.

**Acknowledgements**

The authors would like to thank Mr Satoru Michiyuki, employee of Eiken Chemical Co., Ltd., Otawara, Japan, for his valuable comments and suggestions concerning the LAMP
Rapid detection of the severe acute
First-line erlotinib versus Afatinib versus

Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

Authors' contributions
SH analyzed the data and wrote the initial draft of the manuscript. YS designed the study, analyzed and interpreted the data and assisted in preparing the manuscript. AM performed all experiments and analyzed all results in the study. YS made pathological diagnosis in all cases and provided all tissue samples. NT, TI and EH contributed to data collection and interpretation. MY performed some of the experiments, and critically reviewed the manuscript, and organized research group in this study. Besides AM, all authors approved the final version of the manuscript and they agree to be accountable for all aspects of the work.

Ethical approval and consent to participate
The present study was approved by The Institutional Review Board of the Saitama Cardiovascular and Respiratory Center (approval no. 2016015). Written informed consent was provided by all patients.

Patient consent for publication
Not applicable.

Competing interests
AM is an employee of Eiken Chemical Co., Ltd, and was the only author who conducted all the experiments. Eiken Chemical Co., Ltd, provided the research grant for the present study. AM is an employee of Eiken Chemical Co., Ltd, and was the only author who conducted all the experiments. Eiken Chemical Co., Ltd, had no control over the interpretation, writing, or publication of the present study.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.